Gene therapy clinical trials differ in notable ways from other kinds of clinical trials. For one thing, patients in a typical Phase III clinical trial usually receive multiple doses of the investigational drug and follow-up over a relatively short timeframe. In a gene therapy trial, it’s potentially a “one and done” therapy – patients receive the treatment just once, but long-term, multi-year follow-up is required to detect, record and adequately manage signals of early or delayed adverse reactions. In this article, Mariah Baltezegar and Marie Emms at Syneos Health describes the notable difference between gene therapy clinical trials and other kinds of clinical trials.